Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.

Here are 3 things you should know about the multimodal treatment of patients with SCLC.